Federated Hermes Inc. raised its position in argenx SE (NASDAQ:ARGX - Free Report) by 7.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 356,507 shares of the company's stock after buying an additional 24,416 shares during the quarter. Federated Hermes Inc. owned about 0.60% of argenx worth $135,626,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of ARGX. KB Financial Partners LLC increased its holdings in argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company's stock valued at $27,000 after buying an additional 45 shares during the period. Parkside Financial Bank & Trust bought a new position in argenx in the 3rd quarter valued at about $28,000. FNY Investment Advisers LLC bought a new position in argenx in the 4th quarter valued at about $38,000. Captrust Financial Advisors increased its holdings in argenx by 116.7% in the 1st quarter. Captrust Financial Advisors now owns 143 shares of the company's stock valued at $45,000 after buying an additional 77 shares during the period. Finally, Nkcfo LLC increased its holdings in argenx by 22.1% in the 3rd quarter. Nkcfo LLC now owns 116 shares of the company's stock valued at $57,000 after buying an additional 21 shares during the period. 60.32% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have commented on ARGX. Piper Sandler raised their target price on shares of argenx from $518.00 to $522.00 and gave the company an "overweight" rating in a report on Friday, January 26th. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a "buy" rating to a "hold" rating in a research note on Wednesday, December 20th. Wedbush restated an "outperform" rating and issued a $521.00 price target on shares of argenx in a research note on Thursday. Robert W. Baird reduced their price target on shares of argenx from $505.00 to $490.00 and set an "outperform" rating on the stock in a research note on Friday, March 1st. Finally, JMP Securities restated a "market outperform" rating and issued a $471.00 price target on shares of argenx in a research note on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $528.16.
Get Our Latest Research Report on ARGX
argenx Stock Performance
Shares of NASDAQ ARGX traded down $7.79 during midday trading on Thursday, reaching $358.41. The stock had a trading volume of 261,754 shares, compared to its average volume of 319,265. The firm has a market cap of $21.25 billion, a price-to-earnings ratio of -69.73 and a beta of 0.65. argenx SE has a twelve month low of $327.73 and a twelve month high of $550.76. The company's 50 day moving average price is $388.25 and its 200 day moving average price is $421.81.
argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same quarter in the prior year, the firm earned ($0.70) EPS. Equities analysts forecast that argenx SE will post -2.11 earnings per share for the current fiscal year.
argenx Profile
(
Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
